Taro Kamisasanuk1, Eisuke Uchino, Taiji Sakamoto. 1. Department of Ophthalmology, Faculty of Medicine, Kagoshima University Graduate School of Medicine and Dental Sciences, Kagoshima, Japan.
Abstract
PURPOSE: To report a case of choroidal neovascularization (CNV) associated with optic disk melanocytoma successfully treated with bevacizumab. METHODS: A 63-year-old man complained of visual impairment in his left eye. His visual acuity was 0.9 OS. Fundus examination showed optic disk melanocytoma associated with serous retinal detachment and mild hemorrhage. Fluorescein and indocyanine green angiography revealed CNV adjacent to the optic disc. Intravitreous bevacizumab (IVB) was performed 3 times. RESULTS: Choroidal neovascularization and serous retinal detachment disappeared at 5 months after IVB. Visual acuity recovered to 1.5 OS and has been stable for 1 year follow-up. No adverse events were found related to IVB. CONCLUSIONS: Intravitreous bevacizumab can be a beneficial treatment for CNV associated with optic disc melanocytoma.
PURPOSE: To report a case of choroidal neovascularization (CNV) associated with optic disk melanocytoma successfully treated with bevacizumab. METHODS: A 63-year-old man complained of visual impairment in his left eye. His visual acuity was 0.9 OS. Fundus examination showed optic disk melanocytoma associated with serous retinal detachment and mild hemorrhage. Fluorescein and indocyanine green angiography revealed CNV adjacent to the optic disc. Intravitreous bevacizumab (IVB) was performed 3 times. RESULTS: Choroidal neovascularization and serous retinal detachment disappeared at 5 months after IVB. Visual acuity recovered to 1.5 OS and has been stable for 1 year follow-up. No adverse events were found related to IVB. CONCLUSIONS: Intravitreous bevacizumab can be a beneficial treatment for CNV associated with optic disc melanocytoma.
Authors: Shyamal C Bir; Christopher B Pattillo; Sibile Pardue; Gopi K Kolluru; John Docherty; Dave Goyette; Peter Dvorsky; Christopher G Kevil Journal: Am J Physiol Heart Circ Physiol Date: 2012-05-18 Impact factor: 4.733
Authors: Julio A Urrets-Zavalia; Nicolas Crim; Evangelina Esposito; Leandro Correa; M Eugenia Gonzalez-Castellanos; Dana Martinez Journal: Clin Ophthalmol Date: 2015-03-06